Evidence map›Paper›PMID 41267887›Full record

ArticleThe journal of allergy and clinical immunology. Global2025

First reported allergen immunotherapy anaphylaxis treated with neffy nasal spray: A case series.

Jake Rosenblum, Gregory Puglisi, Joseph Grillo

Abstract readCase Reports
In one paragraph

Article in The journal of allergy and clinical immunology. Global, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jake RosenblumMid Island Allergy Group, Plainview, NY.
Gregory PuglisiMid Island Allergy Group, Plainview, NY.
Joseph GrilloMid Island Allergy Group, Plainview, NY.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The neffy intranasal epinephrine delivery system was recently approved by the US Food and Drug Administration; however, published information on its real-world use is limited. Immunotherapy patients reacting in our clinic experienced prompt symptom resolution with neffy, highlighting its viability as an alternative to intramuscular injection in managing anaphylactic reactions.

Indexed as

allergyanaphylaxisepinephrineimmunotherapyintranasalneffy

Identifiers

PMID41267887
PMCPMC12629718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.